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E-mail address: jq_he@ccmu.edu.cn (J. He).The beta-2 adrenergic receptor (b2AR) has a carboxyl terminus motif that can interact with PSD-95/
discs-large/ZO1 homology (PDZ) domain-containing proteins. In this paper, we identiﬁed mem-
brane-associated guanylate kinase inverted-3 (MAGI-3) as a novel binding partner of b2AR. The car-
boxyl terminus of b2AR binds with high afﬁnity to the ﬁfth PDZ domain of MAGI-3, with the last four
amino acids (D-S-L-L) of the receptor being the key determinants of the interaction. In cells, the
association of full-length b2AR with MAGI-3 occurs constitutively and is enhanced by agonist stim-
ulation of the receptor. Our data also demonstrated that b2AR-stimulated extracellular signal-regu-
lated kinase-1/2 (ERK1/2) activation was substantially retarded by MAGI-3 expression. These data
suggest that MAGI-3 regulates b2AR-mediated ERK activation through the physical interaction
between b2AR and MAGI-3.
Structured summary:
MINT-7716556: beta2AR (uniprotkb:P07550) physically interacts (MI:0915) with MAGI-3 (uni-
protkb:Q5TCQ9) by anti tag coimmunoprecipitation (MI:0007)
MINT-7716593: beta2AR (uniprotkb:P18762) physically interacts (MI:0915) with MAGI-3 (uni-
protkb:Q9EQJ9) by anti bait coimmunoprecipitation (MI:0006)
MINT-7716630: MAGI-3 (uniprotkb:Q5TCQ9) and beta2AR (uniprotkb:P07550) colocalize (MI:0403) by
ﬂuorescence microscopy (MI:0416)
MINT-7716382, MINT-7716335:MAGI-3 (uniprotkb:Q5TCQ9) physically interacts (MI:0915) with beta2AR
(uniprotkb:P07550) by pull down (MI:0096)
MINT-7716320, MINT-7716422, MINT-7716502, MINT-7716450, MINT-7716470: beta2AR (uni-
protkb:P07550) binds (MI:0407) to MAGI-3 (uniprotkb:Q5TCQ9) by pull down (MI:0096)
 2010 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction
Beta-adrenergic receptors (bARs) play important roles in the
cardiovascular, respiratory, metabolic, reproductive and central
nervous systems. The effects of b2AR are mediated by the G-pro-
tein Ga, which leads to activation of cAMP/protein kinase A
(PKA) signaling. Recently, extracellular signal-regulated kinase
(ERK) 1/2 was found to be activated by stimulation of the b2AR.on behalf of the Federation of Euro
PKA, protein kinase A; CT,
’s medium; ERK, extracellular
ceptors; GST, glutathione S-
AGI-3, membrane-associated
e/ZO1 homology; WT, wild
iochemistry, Capital Medical
069, PR China.b2AR stimulation of ERK1/2 may play a role in cardiac hypertrophy
development, and in humans, elevated ERK activation has been re-
ported in heart failure [1–3]. Therefore, elucidating the mechanism
of ERK activation would be useful for ﬁnding new drug targets.
Some studies reported that ERK1/2 activation occurs through
PKA-mediated phosphorylation of the b2AR [4]. Other ﬁndings sug-
gest that Src activation plays a role in b2AR stimulation of ERK1/2
[5,6]. G-protein-independent, b-arrestin-dependent ERK activation
stimulated by the b2AR was recently reported [7,8]. Thus, several
models exist for the mechanism by which b2AR activates the sig-
naling of ERK1/2.
bARs can be recruited into signaling complexes through PSD-
95/discs-large/ZO1 homology (PDZ) domain binding motifs in the
carboxyl terminus (CT) of the receptor, which interacts directly
with PDZ domain-containing scaffolding proteins. The b1AR PDZ
motif interacts with multiple PDZ proteins, including CAL, PDZ-
GEF1, GIPC, membrane-associated guanylate kinase inverted-2pean Biochemical Societies.
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tion, intracellular trafﬁcking, or signaling [9–14]. In contrast,
b2AR is known to associate only with the Na+/H+-exchanger regu-
latory factor 1 (NHERF1), which affects b2AR function after agonist
stimulation [15,16].
Since b1AR and b2AR exhibit a high sequence identity, and PDZ
proteins MAGI-3 and GIPC regulate b1AR-stimulated ERK activa-
tion, we hypothesized that PDZ proteins might bind b2AR, and reg-
ulate b2AR-mediated ERK activation. In this study, we found a
novel interaction between b2AR and MAGI-3, and demonstrated
that interaction of b2AR and MAGI-3 inhibited b2AR-mediated
ERK activation.Fig. 1. MAGI-3 is a novel binding protein of b2AR-CT. Puriﬁed GST or GST-b2AR-CT
beads were used in pull down assay with lysates of COS-7 cells transfected with
GFP-MAGI-3. Precipitates were separated on 8% sodium dodecyl sulfate–polyacryl-
amide gels, and visualized with the anti-GFP antibody. Coomassie Blue staining
demonstrated equal loading of the fusion proteins. The data shown here are
representative of four experiments. Molecular mass standards (in kDa) are on the
left.2. Materials and methods
2.1. Preparation of plasmids and fusion proteins
Human MAGI-3 and b2AR cDNAs were kindly provided by
Dr. Randy Hall (Emory University, GA, USA) [13]. b2AR-CT (the
last 100 amino acids of b2AR), and its mutants were ampliﬁed
by PCR and subcloned into pGEX-4T-1 and veriﬁed by DNA
sequencing.
2.2. Cells and transfection
COS-7 and HEK-293 cells were maintained in complete medium
(Dulbecco’s modiﬁed Eagle’s medium plus 10% fetal bovine serum
and 1% penicillin/streptomycin) in a 37 C/5% CO2 incubator. Trans-
fections were performed following the protocol reported before
[13].
2.3. Fusion proteins pull down assay and Western blotting
Glutathione S-transferase (GST) fusion proteins pull down assay
was performed as reported before [13]. For hexahistidine (His) fu-
sion proteins pull down assay, fusion proteins were puriﬁed using
Chelating Sepharose Fast Flow with immobilized Ni2+ beads (GE
Healthcare, NJ, USA). The eluted proteins were analyzed by Wes-
tern blotting. The anti-His and anti-GFP antibody were purchased
from MBL (Medical and biological laboratories, Japan). Secondary
antibodies were purchased from GE Healthcare. Western blotting
results were detected by chemiluminescence and analyzed with
NIH Image 1.62 [17].
2.4. Co-immunoprecipitation
Co-immunoprecipitation was performed as described before
[17]. Brieﬂy, the mouse heart was homogenized in ice-cold lysis
buffer. Supernatants were incubated with anti-b2AR antibody
(Santa Cruz Biotechnology, CA, USA), prebounded with protein
A&G beads (Calbiochem, CA, USA). After washing, the immunopre-
cipitated proteins were analyzed by Western blotting. Anti-Flag
antibody (MBL) and anti-MAGI-3 antibody (BD Biosciences, NJ,
USA) were used in this study.
2.5. Immunoﬂuorescence colocalization
Immunoﬂuorescence colocalization was done as described pre-
viously [17]. Brieﬂy, plasmids were transfected into HEK-293 cells.
After ﬁxation and permeabilization, cells were stained with a
mouse anti-Flag antibody followed by a rhodamine-conjugated
anti-mouse IgG, and a rabbit anti-His antibody followed by FITC-
conjugated anti-rabbit IgG, and Hochest 33258 (5 lg/mL), then
visualized by a confocal microscope (Leica Microsystems, LAS
AF-TCS SP5).3. Results
3.1. MAGI-3 is a novel binding partner of b2AR
In our previous study, we found b1AR-CT (ESKL), mimicking the
b2AR-CT, could bound to MAGI-3 PDZ5. We also computationally
screened protein database for b2AR-binding proteins using an inte-
grated machine learning system [18–20]. The results predicted a
possible interaction between MAGI-3 and b2AR-CT (data not
shown).
To further explore this potential interaction, COS-7 cells were
transfected with GFP-MAGI-3, and then subjected to GST-pull
down assay. As shown in Fig. 1, a robust MAGI-3 signal was de-
tected from the GST-b2AR-CT pull down complex, indicating inter-
action exists between MAGI-3 and b2AR-CT.
We determined the PDZ domain of MAGI-3 that was involved in
the interaction by subjecting individual MAGI-3 His-PDZ1-5 fusion
proteins to pull down assays with GST-b2AR-CT respectively
(Fig. 2A). A strong MAGI-3 PDZ5 signal was detected in the GST-
b2AR-CT pull down complex, while the other PDZ domains were
detected without or with very weak signals. The reverse pull down
strategy was used to validate these ﬁndings (Fig. 2B). Puriﬁed
MAGI-3 PDZ His-fusion proteins beads were used to isolate pro-
teins from lysates of COS-7 cells, transfected with GFP-b2AR. Con-
sistent with the GST-pull down results, MAGI-3 His-PDZ5 bound to
GFP-b2AR, but no detectable b2AR was bound to His-PDZ4. These
results indicate a strong association between b2AR-CT and MAGI-
3 PDZ5 (Fig. 2B).
3.2. Mutations of b2AR-CT DSLL disrupt b2AR-CT/MAGI-3 interaction
Since the DSLL motif at the b2AR-CT is a canonical class I PDZ
domain binding motif, we explored the structural determinants
of the b2AR-CT/MAGI-3 PDZ5 association by generating a series
of mutant b2AR-CT fusion proteins with Ala substitutions in this
motif. GST-b2AR-CT wild type (WT) or GST-b2AR-CT mutant beads
were used in pull down assays with MAGI-3 His-PDZ5, and the pre-
cipitation complex was detected with anti-His antibody (Fig. 3A).
GST-b2AR-CT WT fusion proteins associated strongly with PDZ5
of MAGI-3. However, this association was completely abolished
by mutation of the terminal Leu residue to Ala. Amino acid muta-
tions of b2AR-CT at the 2 and 3 positions also abolished MAGI-3
Fig. 2. The b2AR interacts with MAGI-3 by binding to speciﬁc PDZ domains. (A) The
b2AR-CT interacts strongly with PDZ5 of MAGI-3. GST-b2AR-CT beads were used to
pull down His-MAGI-3 PDZ1-5 fusion proteins. Precipitates were subjected to
Western blotting with anti-His antibody. Coomassie Blue staining showed equal
loading of the PDZ fusion proteins (lower panel). (B) MAGI-3 PDZ5 interacts
selectively with b2AR. In reverse pull downs, puriﬁed His-PDZ4 and His-PDZ5
MAGI-3 beads (bottom panel), were used to pull down with COS-7 cell lysates,
transfected with GFP-b2AR (middle panel), and the pull down complex was
subjected to Western blotting with anti-GFP antibody (top panel). The data are
representative of three independent experiments. Molecular mass standards (in
kDa) are on the left.
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had little effect on MAGI-3 binding to the b2AR-CT. Thus, point
mutations in three of the last four amino acids of the b2AR-CT
selectively inhibited binding to MAGI-3 PDZ5.Fig. 3. MAGI-3 interacts with b2AR-CT via the receptor DSLL motif. (A) Mutations of th
mutant beads were used to pull down MAGI-3 His-PDZ5 fusion proteins. Precipitates we
with full-length MAGI-3 was abolished by mutation of the terminal leucine residue to
panel) were used to pull down with lysates from COS-7 cells, transfected with full-lengt
representative of three independent experiments. Molecular mass standards (in kDa) arTo detect the binding of the b2AR-CT to full-length MAGI-3,
COS-7 cells were transfected with full-length GFP-MAGI-3, and
pull down assay was performed using GST-b2AR-CT WT or
GST-b2AR-CT DSLA mutant beads (Fig. 3B). b2AR-CT WT strongly
interacted with MAGI-3. However, the b2AR-CT DSLA mutant
showed no interaction with MAGI-3. These results suggested the
importance of the DSLL motif for b2AR association with MAGI-3,
with the terminal Leu residue being an especially critical interac-
tion determinant.
3.3. MAGI-3 interacts with b2AR in cells and native tissues
We next examined interaction between full-length b2AR and
full-length MAGI-3 within cells. COS-7 cells were transfected with
His-MAGI-3 and either Flag-b2AR WT or Flag-b2AR (L413A), in
which the terminal Leu was changed to Ala. Co-immunoprecipita-
tion was performed in the presence and absence of stimulation
with the bAR-selective agonist isoproterenol (ISO) (Fig. 4A). Under
basal conditions, a certain amount of MAGI-3 could be co-immuno-
precipitated with Flag-b2AR. A 15-min stimulation with ISO signif-
icantly increased the amount of co-immunoprecipitated MAGI-3.
Quantiﬁcation revealed that the amount of MAGI-3 co-immuno-
precipitated in the presence of ISO was 2.6-fold higher than that
under basal conditions. These data reveal that b2AR associates con-
stitutively with MAGI-3 in cells, and the interaction can be en-
hanced by agonist activation of the b2AR. Consistent with the
fusion protein studies, a mutant version of b2AR with the terminal
Leu residue changed to Ala (L413A) did not co-immunoprecipitate
with MAGI-3, suggesting the speciﬁcity of the association (Fig. 4A).
In addition to the transfection experiments, we also studied the
interaction of endogenous b2AR and MAGI-3 in mouse heart tissue.
Mice were sacriﬁced after injecting intraperitoneally ISO with
0.01 mg/g body weight or 0.9% sodium chloride solution [21],
and solubilized heart lysates were incubated with b2AR antibody
or unrelated antibody (mock) linked to protein A/G-agarose beads.
Co-precipitated MAGI-3 was detected by Western blotting with
anti-MAGI-3. Robust co-immunoprecipitation of MAGI-3 withe DSLL motif at the b2AR-CT abolish binding to MAGI-3 PDZ5. GST-b2AR-CT WT or
re subjected to Western blotting with anti-His antibody. (B) Association of b2AR-CT
alanine. Equal amounts of puriﬁed GST-b2AR-CT WT or mutant DSLA beads (lower
h GFP-MAGI-3 (middle panel). Precipitates were detected as in Fig. 1. The data are
e on the left.
Fig. 4. Co-immunoprecipitation of MAGI-3 with full-length b2AR is enhanced by agonist stimulation. (A) b2AR interacts with MAGI-3 in COS-7 cells. COS-7 cells transfected
with His-MAGI-3 (lanes 1 and 2), Flag-b2AR WT and His-MAGI-3 (lanes 3 and 4), or Flag-b2AR-L413A and His-MAGI-3 (lanes 5 and 6) were solubilized and incubated with
anti-Flag antibody coupled to beads. Immunoprecipitation of Flag-b2AR (middle panel) demonstrated equal expression of receptors. Co-immunoprecipitation of MAGI-3 (top
panel) was evident under basal conditions (lane 3) and enhanced in samples from cell stimulated with 10 lM ISO for 15 min prior to solubilization (lane 4). Co-
immunoprecipitation was not seen when MAGI-3 was co-expressed with the L413A mutant receptor in the absence (lane 5) or presence of ISO (10 lM, 15 min) (lane 6). (B)
b2AR interacts with MAGI-3 in native tissues. Mice were treated in the presence or absence of ISO (0.01 mg/g) for 30 min and then sacriﬁced. Solubilized lysates from
homogenized mice heart tissues were immunoprecipitated with anti-b2AR and analyzed by Western blotting with anti-MAGI-3 antibody. Data are representative of three
independent experiments. Molecular mass standards (in kDa) are on the left.
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basal conditions, there is no MAGI-3 signal was detectable in b2AR
co-immunoprecipitation complex (Fig. 4B), these results indicated
that a physical complex between b2AR and MAGI-3 exist in native
tissues after receptor was activated with agonist.
The interaction of MAGI-3 with b2AR in cells was further exam-
ined by immunoﬂuorescence colocalization. HEK-293 cells were
transfected with both b2AR and MAGI-3, and immunostaining for
both proteins was analyzed in the absence and presence of ISO
stimulation. b2AR was localized primarily to the plasma mem-
brane under basal conditions (Fig. 5A), while MAGI-3 was diffuse
throughout the cytoplasm and along the plasma membrane
(Fig. 5B). A substantial but not striking overlap of b2AR and
MAGI-3 immunostaining was consistently observed under basal
conditions (Fig. 5C). After a 30-min stimulation with ISO, b2AR
was still found mainly along the plasma membrane, although sub-
stantially more b2AR was observed in the cytoplasm, consistent
with receptor internalization (Fig. 5D). MAGI-3 localization was
not apparently altered following ISO stimulation (Fig. 5E), with
more noticeable colocalization with b2AR than under basal condi-
tions (Fig. 5F).
3.4. MAGI-3 inhibits ERK activation mediated by b2AR
We next explored the potential functional signiﬁcance of b2AR/
MAGI-3 interaction. Since MAGI-3 regulates ERK1/2 activation
mediated by G-protein-coupled receptors, such as b1AR and lyso-
phosphatidic acids (LPA) 2 receptor activation [13,22], we tested
whether MAGI-3 also regulated ERK1/2 activation mediated by
b2AR activation. Co-expression with MAGI-3 had a substantial ef-
fect on b2AR-mediated activation of ERK1/2 (Fig. 6). When b2AR
was expressed alone, ISO-stimulated ERK1/2 activation increased
more than 4.7-fold over basal conditions. Co-expression of MAGI-
3 signiﬁcantly reduced ERK1/2 activation to less than 1.7-fold over
basal conditions (Fig. 6A). In contrast, MAGI-3 co-transfection had
no signiﬁcant effect on ERK1/2 activation by the b2AR-L413A mu-
tant (4.6 vs. 5.1-fold P > 0.05), suggesting that b2AR/MAGI-3 inter-
action inhibited b2AR-mediated ERK1/2 activation (Fig. 6B).Western blotting revealed that MAGI-3 co-expression had no effect
on the total b2AR levels, and b2ARWT and the b2AR-L413Amutant
were expressed at comparable levels. These data suggest that the
ability of MAGI-3 to modulate b2AR-mediated ERK1/2 activation
is dependent on physical interaction between b2AR and MAGI-3.4. Discussion
In this study, MAGI-3 was identiﬁed as a novel binding protein
of b2AR. MAGI-3 was previously reported to interact with b1AR
[13], but these interactions are substantially different. MAGI-3
binds b1AR through its ﬁrst PDZ domain [13], but binds b2AR
through its ﬁfth PDZ domain. The association of b1AR/MAGI-3 is
constitutive, but the association of b2AR/MAGI-3 was promoted
by agonist stimulation (Figs. 4A and 5). However, the molecular
mechanism of how the interaction of b2AR and MAGI-3 regulated
in cells still remains illusive. The serine at position 2 of b2AR car-
boxyl terminal is one of the key determinants of b2AR/MAGI-3
interaction (Fig. 3), and this amino acid could be phosphorylated
by GRK5 [23]. Additionally, it was reported PDZ protein PSD-95
associated with b1AR and this interaction was regulated by phos-
phorylation of the serine at position 2 of b1AR-CT with GRK5
[24]. We proposed that GRK might involve in regulation of b2AR/
MAGI-3 interaction after receptor was activated with ISO stimula-
tion, but this hypothesis need to be further explored.
Heterodimerization of b1AR and b2AR optimizes b-adrenergic
modulation of cardiac contractility [25], and alter pharmacological
properties [26], so understanding the factors that regulate b1AR
and b2AR heterodimers is essential. MAGI-3 binds b1AR and
b2AR through its different PDZ domains, so it raises the possibility
that MAGI-3 is a scaffolding molecule to enhance the association of
b1AR and b2AR. However, we have not examined the effects of
MAGI-3 on b1AR/b2AR heterodimerization.
The b2AR-activated MAPK signaling mechanisms are diverse
and are not conclusively understood. Heterodimerization between
b1AR and b2AR inhibits their ability to activate the ERK1/2 MAPK
signaling pathway [27], so one possible mechanism for MAGI-3
Fig. 5. Immunoﬂuorescence colocalization of b2AR and MAGI-3 in cells. Flag-b2AR and His-MAGI-3 were co-expressed in HEK-293 cells and visualized via
immunoﬂuorescence microscope in the absence (A–C) or presence of (D–F) ISO (10 lM, 30 min). Data are representative of six independent experiments.
Fig. 6. MAGI-3 inhibits b2AR-stimulated ERK activation. (A) Flag-b2AR, Flag-L413A
mutant receptor, and/or His-MAGI-3 were transiently transfected into COS-7 cells.
Cells were treated with serum-free medium overnight after 48 h of transfection.
Serum-starved cells were stimulated with 10 lM ISO for 5 min at 37 C. ERK1/2
activation was assayed as described in Section 2. (B) Quantiﬁcation of MAGI-3 effect
on b2AR and L413A mediated ERK1/2 activation. The amount of phospho-ERK1/2
immunoreactivity observed following ISO stimulation was expressed as fold of
phospho-ERK1/2 immunoreactivity in the absence of stimulation. Data and error
bars represent means ± standard error (S.E.) for three independent experiments.
Asterisks indicate a signiﬁcant decrease (P < 0.01) relative to phospho-ERK immu-
noreactivity in the absence of transfected MAGI-3.
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might act as a linker to promote formation of b1AR and b2AR
heterodimers. Another mechanism might involve in b-arrestin-
mediated ERK1/2 activation. Several studies have demonstratedthat b2AR-stimulated ERK1/2 activity requires recruitment of b-
arrestin, which acts as a scaffolding protein for assembling the
ERK1/2 signaling cascade [28–30]. Since the CT region of b2AR
is important for b-arrestin binding [8], and MAGI-3 interacts with
the CT of b2AR, MAGI-3/b2AR interaction might interfere with b-
arrestin binding to b2AR, reducing its ability to assemble the
ERK1/2 signaling complex, and result in the inhibition of b2AR-
mediated ERK activation via b-arrestin. However, this model
needs to be further investigated.
In summary, our results demonstrate that MAGI-3 speciﬁcally
interacts with b2AR and inhibits b2AR-mediated ERK activation.
These results add to the knowledge about b2AR-interacting pro-
teins, and their potential effects on signaling and functions of the
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